Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is
the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks. Secondary efficacy
variable: % IOP ≤ 18 millimeters mercury (mmHg). Exploratory endpoint: Ocular discomfort
scale after first dose.